-
Product Insights
Granulocyte Macrophage Colony Stimulating Factor – Drugs In Development, 2023
Global Markets Direct’s Granulocyte Macrophage Colony Stimulating Factor provides in depth analysis on Granulocyte Macrophage Colony Stimulating Factor targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Granulocyte...
-
Product Insights
Granulocyte Colony Stimulating Factor Receptor – Drugs In Development, 2023
Global Markets Direct’s Granulocyte Colony Stimulating Factor Receptor provides in depth analysis on Granulocyte Colony Stimulating Factor Receptor targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Granulocyte...
-
Product Insights
Macrophage Colony Stimulating Factor 1 Receptor – Drugs In Development, 2023
Global Markets Direct’s Macrophage Colony Stimulating Factor 1 Receptor provides in depth analysis on Macrophage Colony Stimulating Factor 1 Receptor targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha – Drugs In Development, 2023
Global Markets Direct’s Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha provides in depth analysis on Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview...
-
Product Insights
Likelihood of Approval Analysis for Streptococcal Pneumonia
Overview How likely is it that the drugs in Streptococcal Pneumonia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Streptococcal Pneumonia Overview Streptococcus pneumoniae, or pneumococcus, is a Gram-positive spherical bacteria,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Efbemalenograstim Alfa LA in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efbemalenograstim Alfa LA in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efbemalenograstim Alfa LA in Breast Cancer Drug Details: Efbemalenograstim Alfa...
-
Product Insights
Likelihood of Approval Analysis for Neutropenia
Overview How likely is it that the drugs in Neutropenia will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neutropenia Overview Neutropenia is an abnormally low concentration of neutrophils (a type of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Filgrastim Biosimilar in Chemotherapy Induced Neutropenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Filgrastim Biosimilar in Chemotherapy Induced Neutropenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Filgrastim Biosimilar in Chemotherapy Induced Neutropenia Drug Details: Filgrastim is...
-
Product Insights
Colonial Eagle – Kelford Solar PV Park
Colonial Eagle - Kelford Solar PV Park is a solar PV project located in North Carolina, United States. The project is owned by Duke Energy Renewables Inc and was developed by SunEnergy1. The project came online in 2015. Empower your strategies with our Colonial Eagle - Kelford Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day...
-
Product Insights
Colonial Eagle – Pasquotank Solar PV Park
Colonial Eagle - Pasquotank Solar PV Park is a solar PV project located in North Carolina, United States. The project is owned by Duke Energy Renewables Inc and was developed by SunEnergy1. The project came online in 2014. Empower your strategies with our Colonial Eagle - Pasquotank Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day...